S&P 500   3,380.16 (+0.18%)
DOW   29,398.08 (-0.09%)
QQQ   234.64 (+0.29%)
S&P 500   3,380.16 (+0.18%)
DOW   29,398.08 (-0.09%)
QQQ   234.64 (+0.29%)
S&P 500   3,380.16 (+0.18%)
DOW   29,398.08 (-0.09%)
QQQ   234.64 (+0.29%)
S&P 500   3,380.16 (+0.18%)
DOW   29,398.08 (-0.09%)
QQQ   234.64 (+0.29%)
Log in

NASDAQ:VBIV - VBI Vaccines Stock Price, Forecast & News

$1.53
-0.06 (-3.77 %)
(As of 02/17/2020 04:00 PM ET)
Today's Range
$1.52
Now: $1.53
$1.62
50-Day Range
$1.26
MA: $1.47
$1.91
52-Week Range
$0.47
Now: $1.53
$2.20
Volume1.81 million shs
Average Volume3.74 million shs
Market Capitalization$272.74 million
P/E RatioN/A
Dividend YieldN/A
Beta1.03
VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company offers Sci-B-Vac, a prophylactic hepatitis B vaccine for adults, children, and newborns; and eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines that closely mimic the structure of the target virus. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:VBIV
CUSIPN/A
Phone617-830-3031

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.36 million
Book Value$1.08 per share

Profitability

Net Income$-63,600,000.00
Net Margins-1,458.97%

Miscellaneous

Employees108
Market Cap$272.74 million
Next Earnings Date2/24/2020 (Estimated)
OptionableOptionable

Receive VBIV News and Ratings via Email

Sign-up to receive the latest news and ratings for VBIV and its competitors with MarketBeat's FREE daily newsletter.


VBI Vaccines (NASDAQ:VBIV) Frequently Asked Questions

What is VBI Vaccines' stock symbol?

VBI Vaccines trades on the NASDAQ under the ticker symbol "VBIV."

How were VBI Vaccines' earnings last quarter?

VBI Vaccines Inc (NASDAQ:VBIV) released its quarterly earnings results on Wednesday, November, 6th. The biopharmaceutical company reported ($0.15) EPS for the quarter, missing analysts' consensus estimates of ($0.13) by $0.02. The biopharmaceutical company earned $0.65 million during the quarter, compared to analysts' expectations of $0.90 million. VBI Vaccines had a negative net margin of 1,458.97% and a negative return on equity of 70.54%. View VBI Vaccines' Earnings History.

When is VBI Vaccines' next earnings date?

VBI Vaccines is scheduled to release their next quarterly earnings announcement on Monday, February 24th 2020. View Earnings Estimates for VBI Vaccines.

What price target have analysts set for VBIV?

3 analysts have issued 12 month price targets for VBI Vaccines' stock. Their forecasts range from $3.00 to $5.00. On average, they expect VBI Vaccines' share price to reach $4.33 in the next twelve months. This suggests a possible upside of 183.2% from the stock's current price. View Analyst Price Targets for VBI Vaccines.

What is the consensus analysts' recommendation for VBI Vaccines?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for VBI Vaccines in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for VBI Vaccines.

Has VBI Vaccines been receiving favorable news coverage?

Media headlines about VBIV stock have been trending extremely negative on Monday, according to InfoTrie. The research firm rates the sentiment of media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. VBI Vaccines earned a coverage optimism score of -5.0 on InfoTrie's scale. They also gave news stories about the biopharmaceutical company a news buzz of 6.0 out of 10, indicating that recent media coverage is somewhat likely to have an effect on the stock's share price in the next few days. View News Stories for VBI Vaccines.

Who are some of VBI Vaccines' key competitors?

What other stocks do shareholders of VBI Vaccines own?

Based on aggregate information from My MarketBeat watchlists, some companies that other VBI Vaccines investors own include QuickLogic (QUIK), Agile Therapeutics (AGRX), vTv Therapeutics (VTVT), Inovio Pharmaceuticals (INO), Nabriva Therapeutics (NBRV), Opko Health (OPK), Selecta Biosciences (SELB), Novavax (NVAX), SCYNEXIS (SCYX) and Anavex Life Sciences (AVXL).

Who are VBI Vaccines' key executives?

VBI Vaccines' management team includes the folowing people:
  • Mr. Jeff R. Baxter, CEO, Pres & Director (Age 58)
  • Dr. David Evander Anderson, Chief Scientific Officer (Age 49)
  • Dr. Francisco Diaz-Mitoma, Chief Medical Officer (Age 64)
  • Mr. Christopher McNulty, CFO & Head of Bus. Devel. (Age 42)
  • Ms. Athena Kartsaklis, Sr. VP of Fin., Chief Compliance Officer & Principal Financial Officer (Age 54)

Who are VBI Vaccines' major shareholders?

VBI Vaccines' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include State Street Corp (1.15%), Cambridge Investment Research Advisors Inc. (0.96%), First Midwest Bank Trust Division (0.80%), Charles Schwab Investment Management Inc. (0.24%), Premier Asset Management LLC (0.14%) and UBS Group AG (0.13%). Company insiders that own VBI Vaccines stock include Christopher Mcnulty, Francisco Diaz-Mitoma, Jeff Baxter, Life Sciences Maste Perceptive, Nell Beattie, Perceptive Advisors Llc, Steven Gillis and Tomer Kariv. View Institutional Ownership Trends for VBI Vaccines.

Which major investors are selling VBI Vaccines stock?

VBIV stock was sold by a variety of institutional investors in the last quarter, including Virtu Financial LLC. View Insider Buying and Selling for VBI Vaccines.

Which major investors are buying VBI Vaccines stock?

VBIV stock was acquired by a variety of institutional investors in the last quarter, including First Midwest Bank Trust Division, State Street Corp, Premier Asset Management LLC, Charles Schwab Investment Management Inc., Raymond James & Associates, Goldman Sachs Group Inc., Cambridge Investment Research Advisors Inc. and Grimes & Company Inc.. Company insiders that have bought VBI Vaccines stock in the last two years include Christopher Mcnulty, Francisco Diaz-Mitoma, Jeff Baxter, Life Sciences Maste Perceptive, Nell Beattie, Perceptive Advisors Llc, Steven Gillis and Tomer Kariv. View Insider Buying and Selling for VBI Vaccines.

How do I buy shares of VBI Vaccines?

Shares of VBIV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is VBI Vaccines' stock price today?

One share of VBIV stock can currently be purchased for approximately $1.53.

How big of a company is VBI Vaccines?

VBI Vaccines has a market capitalization of $272.74 million and generates $3.36 million in revenue each year. The biopharmaceutical company earns $-63,600,000.00 in net income (profit) each year or ($0.97) on an earnings per share basis. VBI Vaccines employs 108 workers across the globe.View Additional Information About VBI Vaccines.

What is VBI Vaccines' official website?

The official website for VBI Vaccines is http://www.vbivaccines.com/.

How can I contact VBI Vaccines?

VBI Vaccines' mailing address is 222 Third Street Suite 2241, Cambridge MA, 02142. The biopharmaceutical company can be reached via phone at 617-830-3031 or via email at [email protected]


MarketBeat Community Rating for VBI Vaccines (NASDAQ VBIV)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  424 (Vote Outperform)
Underperform Votes:  240 (Vote Underperform)
Total Votes:  664
MarketBeat's community ratings are surveys of what our community members think about VBI Vaccines and other stocks. Vote "Outperform" if you believe VBIV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VBIV will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/17/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel